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Abstract
Background: Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has an
unacceptably low cure rate. In recent years, a number of new treatment strategies and compounds were
developed for the treatment of AML. There were several randomized controlled clinical trials with the objective to
improve patients’ management and patients’ outcome in AML. Unfortunately, these trials are not always directly
comparable since they do not measure the same outcomes, and currently there are no core outcome sets that can
be used to guide outcome selection and harmonization in this disease area. The HARMONY (Healthcare Alliance for
Resourceful Medicine Offensive against Neoplasms in Hematology) Alliance is a public-private European network
established in 2017 and currently includes 53 partners and 32 associated members from 22 countries. Amongst
many other goals of the HARMONY Alliance, Work Package 2 focuses on defining outcomes that are relevant to
each hematological malignancy. Accordingly, this pilot study will be performed to define a core outcome set in
AML.
Methods: The pilot study will use a three-round Delphi survey and a final consensus meeting to define a core
outcome set. Participants will be recruited from different stakeholder groups, including patients, clinicians,
regulators and members of the European Federation of Pharmaceutical Industries and Associations. At the pre-
Delphi stage, a literature research was conducted followed by several semi-structured interviews of clinical public
and private key opinion leaders. Subsequently, the preliminary outcome list was discussed in several multi-
stakeholder face-to-face meetings. The Delphi survey will reduce the preliminary outcome list to essential core
outcomes. After completion of the last Delphi round, a final face-to-face meeting is planned to achieve consensus
about the core outcome set in AML.
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Discussion: As part of the HARMONY Alliance, the pilot Delphi aims to define a core outcome set in AML on the
basis of a multi-stakeholder consensus. Such a core outcome set will help to allow consistent comparison of future
clinical trials and real-world evidence research and ensures that appropriate outcomes valued by a range of
stakeholders are measured within future trials.
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Introduction
Acute myeloid leukemia (AML) is the most common
acute leukemia in adults. Clonal expansion of undif-
ferentiated myeloid precursor cells causes impaired
hematopoiesis and bone marrow failure. For decades,
the basis of AML treatment has remained virtually
unchanged. However, over the last few years, driver
mutations have been identified and molecular sub-
groups defined, resulting in an improved prognostic
stratification and updated European LeukemiaNET
guidelines [1, 2].
Although scientific and technical advances have re-
sulted in a number of new treatment strategies in recent
years, AML still poses a challenge to curative ap-
proaches: cure rates remain poor compared with those
of other hematological malignancies. Currently, several
innovative compounds are being investigated in random-
ized controlled clinical trials with the objective to im-
prove both patients’ outcome and patients’ management
in AML. However, the ability to compare these clinical
trials is limited by differences in their measured out-
comes. This lack of standardization relates to the current
lack of a core outcome set (COS) that can be used to
guide outcome selection and harmonization in AML in
current and future trials.
The HARMONY (Healthcare Alliance for Resourceful
Medicine Offensive against Neoplasms in Hematology)
Alliance is a public-private European network estab-
lished in 2017 and currently includes 53 partners, inter
alia six cancer patient umbrella organizations, and 32
associated members from 22 countries. One of HAR-
MONY’s goal is to use big data to improve understand-
ing and treatment of hematological malignancies. In
order to achieve this aim, HARMONY is structured into
eight work packages, of which Work Package 2 (WP 2)
is focused on defining outcomes that are relevant to
each hematological malignancy. In the future, WP 2
aims to define a common COS valid for all
hematological malignancy. Accordingly, this pilot study
will be performed to define a COS in AML.
A COS is a minimum set of outcomes developed by
consensus, usually using a multi-stakeholder consensus-
based Delphi process. The COS is a reference point and
provides the minimum outcome set that should be col-
lected in further clinical trials on a given condition. Use
of a COS improves comparability of clinical trials and
consistency of reporting, reduces selective reporting bias
and ensures that appropriate outcomes valuable by a
range of stakeholders are measured. Furthermore, a COS
can be used in other clinical settings or type of real-
world evidence research and can be incorporated into
clinical guidelines and improve clinical practice in this
way.
Involvement of different stakeholder groups is critical
to ensure that the defined COS has broad relevance. Key
stakeholders will provide their expert feedback and will
be recruited on the basis of their experiences relevant to
AML or the project. The different stakeholder groups in-
clude health service users, health service practitioners,
researchers, drug developers, regulators, patient advo-
cates and patients. All ratings are provided anonymously;
so without group interactions, different opinions will be
presented more clearly between different stakeholder
groups.
Aims
This project aims to define a COS in AML agreed by
consensus of all stakeholder groups to be measured in
future clinical trials and observational studies. This pilot
study also aims to establish the Delphi method for fur-
ther disease-specific COS defining studies that are
planned for other hematological malignancies in HAR-
MONY. The defined COS will help to improve future
clinical study design to improve patient satisfaction and
management.
Methods
COS development will follow recommendations of the
Core Outcome Measures in Effectiveness Trials (COMET)
initiative from the international Core Outcome Set Stan-
dards for Development (COS-STAD) [3, 4]. The Delphi
method will be used to achieve a consensus from different
stakeholder groups. A prospective study protocol was reg-
istered in the COMET database (http://www.comet-initia-
tive.org/studies/details/1347). The protocol was written in
accordance with the Core Outcome Set-Standardised
Protocol (COS-STAP) recommendations [5] in cooper-
ation between WP 2 and WP 6. In Fig. 1, each step of the
study is illustrated.
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Study design
Recruitment of participants mainly takes place from
members of the HARMONY WPs, but participants out-
side the HARMONY Alliance are also invited to take
part in the Delphi survey within their stakeholder group.
At least three rounds of the Delphi survey are planned
to achieve consensus. At the end, a final face-to-face
consensus meeting will take place.
Scope of the COS
The COS-identified AML will be crucial not only for the
HARMONY project but for all future analyses. As the
definition of COS will determine what data are captured
for AML, it will also impact how the analyses will be
available in the future. Consequently, COS will directly
impact future data sets available to HARMONY and also
the research community. Additionally, future work con-
ducted by HARMONY partners and other stakeholders




Every patient older than 18 years with AML can
participate. Different subtypes of AML are equally
included, regardless of previous treatments,
including stem cell transplantation. Patients treated
as outpatients were included as well as patients
treated in hospitals. Owing to the use of English for
the Delphi survey, participation is limited to
patients understanding English.
2. Clinicians and clinical researchers
Every clinician within or outside the HARMONY
Alliance who has experience in AML treatment can
participate.
3. Drug developers
Members of European Federation of Pharmaceutical
Industries and Associations (EFPIA) and part of the
HARMONY Alliance are invited to participate as
well.
4. Regulators
Recruitment of participants will be performed within
the HARMONY Alliance with the support of WP 7,
which is responsible for dissemination, communication
and training within the HARMONY Alliance. WP 6 pro-
vides assistance in promotion for the survey.
Fig. 1 Steps of the planned Delphi process
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To recruit health-care professionals, AML key opinion
leaders will be contacted and will be asked to invite
other professionals within their peer groups to take part
in the Delphi survey. Thus, participants outside the
HARMONY Alliance are welcome to take part in the
Delphi survey. Patient recruitment will be performed
with the support of patient advocates and several patient
organizations, like Acute Leukemia Advocates Network
or LeukaNet. Especially in the recruitment of patients,
social networks and internal communication tools will
be used to spread the information and invitations for the
Delphi survey. In the next rounds, personal mail re-
minders will be sent out to enhance the response rates.
Trial registration
This project has been registered (May 2019) in the data-
base of the COMET initiative
(http://www.comet-initiative.org/studies/details/1347).
Study management group
As recommended by the COMET initiative, a study
management group has been assembled to oversee the
project [3]. The group comprises a study coordinator, a
hematologist with leading roles in AML treatment and
clinical trials, a drug developer with experience in past
and current trials, patient advocates and methodological
experts with experience of systematic reviews and Delphi
studies. The role of the study management group is to
support the development of the study protocol and to
review the list of outcomes and the associated lay ver-
sions and descriptions.
Selection of the preliminary outcome list for AML
So far, the empirical basis for identifying a long list of
preliminary outcomes relevant in AML for the Delphi
study has been threefold:
1. A literature research was conducted in the COMET
database to get an overview of the cancer outcomes
already used in existing clinical trials. Therefore, all
relevant trials for outcome set definition in AML
were collected to October 17, 2017 [6]. The
primary AML outcome list was generated by
extracting outcomes from the COMET database
research and review of published literature [7–14].
2. Several semi-structured interviews of clinical public
and private key opinion leaders were conducted to
assess the initial selection of the outcome parame-
ters, and additional outcomes were supplemented.
This was followed by several face-to-face meetings
to further expand and discuss the potential outcome
list, including a multi-stakeholder group workshop
and a further meeting with European AML key
opinion leaders within the scope of the HARMONY
Alliance.
3. Patient representatives and patients were consulted
to include patients’ perspective. The preliminary
outcome list was complemented by including
additional outcomes and revising in accordance
with patients’ comments.
On the basis of new scientific knowledge [15] and rec-
ommendations of the COMET initiative [3], the out-
come list was reworked. Prognostic factors (e.g., age and
gender) were removed from the list. Tools of “how to
measure” an outcome (e.g., quality-of-life questionnaires)
were also removed. Instead, AML concepts (outcomes
related to patients’ perception of their symptoms, func-
tioning and health-related quality of life) were included.
After the pre-Delphi stage, a list of 59 outcomes, each
with a short plain language description, grouped into
eight domain categories was completed. You can find
the list used for this Delphi survey as Additional file 1.
Delphi process
The Delphi survey will be managed online by using Del-
phiManager software maintained by the COMET initia-
tive [6]. Invitations with a registration link will be sent
out. After registration, every participant will receive a
unique identification code to take part in the Delphi sur-
vey. For registration, participants are asked to fill in their
email address, their stakeholder group and their home
country. The webpage includes a description of aims
and objectives of the survey and gives an explanation
about how to complete the online Delphi survey. In
every round, the participants will be asked to rate the
importance of each outcome on the basis of their per-
sonal experiences. Each outcome will be ranked into
three categories (“not important”, “important, but not
critical” and “critical”) by using a 9-point Likert scale.
After the first round, a descriptive statistic for every
stakeholder group will be provided. Only participants
who completed the first round will be invited to take
part in the second Delphi round. In the following
rounds, participants will revise their answers by taking
the previous results into account. The process is stopped
after pre-defined consensus criteria.
Consensus criteria
To reduce potential bias in interpretation of the results,
a clear consensus definition is important. We will use
three categories of consensus that were already used in
previous works [16].
1. “Consensus in” means 70% or more of all
respondents scored the outcome as critically
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important and 15% or fewer of all respondents
scored the outcome as of limited importance.
2. “Consensus out” means 70% or more of all
respondents scored the outcome as of limited
importance and 15% or fewer of all respondents
scored the outcome as critically important.
3. No consensus.
Outcomes that do not achieve consensus through sev-
eral Delphi rounds will be discussed in a final face-to-
face consensus meeting to finally ratify the AML COS.
Representatives from all participating stakeholder groups
will be part of this meeting.
Analysis
Analysis of the Delphi study will use descriptive statis-
tics. The results for each Delphi round, for each out-
come and for each stakeholder group will be presented
in frequency tables. The analysis of the Delphi survey
will be performed by using the R statistical software ver-
sion 3.5.2.
As an exploratory analysis, we additionally identify
outcomes considered important for patients. The me-
dian Likert score for the patient group at the end of each
round will be calculated, and those outcomes achieving
a median of at least 7 will be considered important for
patients and will be included in the COS. In this way,
patient-important outcomes can be separately discussed
in the final consensus meeting. Attrition bias will be in-
vestigated by comparing results across participants who
complete successive rounds versus those who withdraw
at round 2 or 3. Until now, no valuable data are available
about the best group size for a Delphi survey; in this
AML pilot Delphi, a group size of 20–50 participants
should be achieved.
Discussion
The described modified Delphi process will help to de-
fine a COS for AML on the basis of consensus of differ-
ent stakeholder groups. To ensure the impact of
patients’ involvement, an additional criterion in analysis
will mark the outcomes with special interest for patients.
The language used in this Delphi survey is English.
Therefore, participation is limited to men and women
with a sufficient command of English to read and under-
stand the survey. This constitutes a restriction of the
study, but translation in other European languages is not
proposed for the pilot Delphi.
A further limitation of the study is recruitment of par-
ticipants in the course of the HARMONY communica-
tion platform and patient umbrella organizations.
Participants will be asked about their home country at
registration.
The anticipated way of COS development ensures that
clinicians, EFPIA members, health authorities and pa-
tients have an equal share in each stage of the process.
Carrying out a pilot Delphi will greatly inform the de-
sign and success of further Delphi surveys for COS def-
inition for other hematological diseases considered in
HARMONY.
The defined COS should be considered a minimum
set of outcomes for AML, which will be collected and
reported in future clinical trials, real-world evidence re-
search and observational studies. In addition, further
outcomes of special interest that are deemed relevant
can be included in future research.
After the definition of a COS in AML, the next chal-
lenge will be the implementation of these outcomes in
clinical guidelines and at last in clinical practice. Finally,
patient treatment and patient satisfaction can be im-
proved by reducing heterogeneity among clinical trials.
The measured outcomes will be more easily comparable,
meta-analyses of pooled studies will be more meaning-
ful, and the level of evidence of future guidelines will be
improved.
Trial status
At the time of manuscript submission, the Delphi survey
was open to recruitment. The starting date was April 12,
2019, and the approximate closing date was June 9,
2019. Protocol version 17 was published April 12, 2019.
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